StockNews.AI
RMD
StockNews.AI
153 days

New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer

1. CPAP therapy lowers death risk by 37% in sleep apnea patients. 2. Heart-related deaths drop by 55% with CPAP therapy use. 3. Majority of sleep apnea cases remain undiagnosed and untreated. 4. More consistent CPAP use results in greater survival benefits. 5. Study compiled by analyzing over 1 million patients worldwide.

8m saved
Insight
Article

FAQ

Why Very Bullish?

This significant meta-analysis strengthens RMD's market position as a leader in sleep health, likely increasing investor confidence. Historical precedents, like the surge in share price after FDA approvals, illustrate how medical validation can propel positive company valuations.

How important is it?

The conclusive evidence on CPAP's life-saving benefits may drive increased consumer demand, market recognition, and regulatory support.

Why Long Term?

The findings underscore the long-term value of CPAP therapy, positively influencing future sales and investor interest as public awareness grows over time. For instance, similar studies in health technology have led to sustained revenue growth for companies involved.

Related Companies

PHGMDTCSLGHBDX
Largest ever meta-analysis on the long-term benefits of CPAP therapy, published in The Lancet Respiratory Medicine, found that in people with sleep apnea, CPAP therapy lowered the overall chance of dying by 37% and the chance of heart-related death by 55%. March 19, 2025 08:00 ET  | Source: Resmed, Inc. SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark meta-analysis in The Lancet Respiratory Medicine, demonstrating that CPAP therapy significantly reduces the risk of death for people with obstructive sleep apnea (OSA). Analyzing data from over 1 million sleep apnea patients worldwide, the study provides the strongest evidence to date that CPAP therapy not only alleviates OSA symptoms but can also prolong life. OSA affects over one billion people worldwide,1 with over 80% of cases undiagnosed and untreated.2 This chronic sleep-related breathing disorder can impair daily functioning and has been associated with serious health conditions, including hypertension, diabetes, cardiovascular disease, and stroke.3 The study reinforces that untreated OSA is a major but modifiable risk factor for both all-cause and cardiovascular-related death, highlighting the importance of consistent CPAP use. As the gold standard for OSA treatment, CPAP therapy is widely recognized for its effectiveness. When used correctly, it works overnight and only requires air; no drugs, surgery, or invasive procedures. The study, led by global experts in sleep and respiratory medicine and supported by Resmed, found that people with OSA who use CPAP therapy have: A 37% lower risk of dying from any cause compared to those with OSA who do not use CPAP.A 55% lower risk of dying from cardiovascular disease, reinforcing CPAP’s supportive benefits for heart health in people living with OSA.A dose-response relationship, meaning that the more consistently CPAP is used, the greater the survival benefits for people living with OSA. “For people with OSA, using CPAP versus not using CPAP can literally be a matter of life or death,” said Carlos Nunez, M.D., Resmed’s Chief Medical Officer. “Decades of research have shown CPAP can improve quality of life, and this study now provides the most comprehensive evidence yet that CPAP also prolongs lives for people living with OSA.” This meta-analysis is the largest of its kind to date, pooling data from over 1 million OSA patients across 30 studies, including 10 randomized controlled trials (RCTs) and 20 real-world evidence studies (RWEs). Researchers analyzed long-term outcomes over the average follow-up period of nearly five years, testing the hypothesis that CPAP therapy reduces both all-cause and cardiovascular mortality in OSA patients. "The results of the study strongly suggest that CPAP therapy is a life-saving intervention for people with OSA,” said Atul Malhotra, M.D, senior author of the study, Research Chief of Pulmonary, Critical Care and Sleep Medicine at the University of California San Diego School of Medicine and Pulmonologist at UC San Diego Health. “It’s not only about sleep apnea treatment but also about supporting heart health and extending life.” “These findings should serve as a wake-up call,” added Jean-Louis Pépin, study co-author, Professor of Clinical Physiology at Grenoble University Hospital and Director of the HP2 Laboratory INSERM U1300. “Every additional hour of CPAP treatment translates to improved chance of survival for people living with OSA. Patients who stay on CPAP therapy aren’t just breathing easier at night; they’re potentially adding years to their lives.” To read the full study, see the publication in The Lancet Respiratory Medicine. To learn more about how life-changing CPAP therapy can be, visit www.resmed.com/video-story-gallery. Study authors: Adam V. Benjafield PhD; Prof Jean-Louis Pepin; Prof Peter A. Cistulli; Alison Wimms PhD; Florent Lavergne MSc; Fatima H. Sert Kuniyoshi PhD, Sibyl H. Munson PhD, Brendan Schuler BS; Shrikar Reddy Badikol MSc; Kelly C. Wolfe BS; Leslee Willes MPH; Colleen Kelly PhD; Tetyana Kendzerska MD; Dayna A. Johnson PhD; Prof Raphael Heinzer MD, Prof Chi-Hang Lee MD, Prof Atul Malhotra MD. About Resmed Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed. For Media For Investors   Caela Shay Mike Ott or Wendy Wilsonnews@resmed.com investorrelations@resmed.com 1 Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, Nunez CM, Patel SR, Penzel T, Pépin JL, Peppard PE, Sinha S, Tufik S, Valentine K, Malhotra A. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019 Aug;7(8):687-698. doi: 10.1016/S2213-2600(19)30198-5. Epub 2019 Jul 9. PMID: 31300334; PMCID: PMC7007763.2 Young T, Evans L, Finn L, Palta M. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Sleep. 1997 ;20(9):705-63 Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2021; 144(3): e56-e67.

Related News